Table 2.

Univariate and Multivariate Analyses progress-free survival prognosis of NSCLC EGFR-mutated patients

	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age
<70	1		1
≥70	0.69(0.41,1.16)	0.1598	0.65 (0.34, 1.23)	0.1872
Gender
female	1
male	1.13(0.73, 1.75)	0.5869
ECOG score
0	1		1
1	1.28 (0.73, 2.24)	0.3838	1.09 (0.59, 2.01)	0.7920
2	0.88 (0.42, 1.83)	0.3838	0.85 (0.38, 1.93)	0.6983
Smoking
No	1
Yes	0.85 (0.45, 1.61)	0.6175
Type of pathological
Adenocarcinoma	1
Others	1.37 (0.50, 3.76)	0.5419
TNM stage
IVA	1		1
IVB	1.62 (0.95, 2.77)	0.5419	1.29 (0.63, 2.65)	0.4792
Brain metastasis
No	1
Yes	1.15 (0.75, 1.77)	0.5156
Bone metastasis
No	1		1
Yes	1.58 (1.01, 2.50)	0.0471	1.30 (0.71, 2.36)	0.3976
Liver metastasis
No	1		1
Yes	1.40 (0.74, 2.65)	0.2976	1.38 (0.65, 2.93)	0.3981
Lung metastasis
No	1		1
Yes	0.67 (0.43, 1.05)	0.2976	0.71 (0.43, 1.15)	0.1665
Pleural metastasis
No	1		1
Yes	1.29 (0.81, 2.05)	0.2897	1.34 (0.81, 2.21)	0.2551
EGFR mutation
19del	1		1
21-L858R	1.06 (0.68, 1.64)	0.8086	1.37 (0.82, 2.27)	0.2288
other	0.75 (0.27, 2.12)	0.5906	1.41 (0.40, 4.94)	0.2288
T790M (initial)
No	1		1
Yes	0.41 (0.13, 1.32)	0.1367	0.58 (0.16, 2.10)	0.4068
TP53 mutation
No	1		1
Yes	1.18 (0.75, 1.87)	0.4664	0.94 (0.56, 1.60)	0.8298
Radiotherapy
No	1		1
Yes	1.27 (0.80, 2.01)	0.4664	1.08 (0.62, 1.87)	0.7893
Initial treatment
1 generation TKI	1		1
2 generation TKI	0.93 (0.47, 1.83)	0.8289	0.64 (0.28, 1.46)	0.2927
3 generation TKI	0.41 (0.23, 0.73)	0.0026	0.39 (0.20, 0.77)	0.0063
1 generation TKI+ Anlotinib	0.64 (0.26, 1.61)	0.8289	0.54 (0.20, 1.44)	0.2183
EGFR amplification
No	1		1
Yes	1.15 (0.66, 2.01)	0.6300	1.38 (0.73, 2.58)	0.3210

Abbreviations: CI confidence interval, HR hazard ratio, EGFR epidermal growth receptor, ECOG Eastern Cooperative Oncology Group, TNM Tumor Node Metastasis, 19del exon 19 deletion, 21-L858R exon 21 Leu858Arg, TKI tyrosine kinase inhibitor, bold was considered significant